Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-24T13:47:51.709Z Has data issue: false hasContentIssue false

Clozapine-induced parotitis: A case study

Published online by Cambridge University Press:  13 August 2021

M. Kacem*
Affiliation:
Department Of Psychiatry, University hospital of mahdia, chebba, Tunisia
H. Mami
Affiliation:
Department Of Psychiatry, University hospital of Nabeul, Nabeul, Tunisia
S. Sellami
Affiliation:
Department Of Psychiatry, University hospital of Nabeul, Nabeul, Tunisia
M. Moalla
Affiliation:
Department Of Psychiatry, University hospital of Nabeul, Nabeul, Tunisia
S. Ben Frej
Affiliation:
Department Of Psychiatry, University Hospital Of Mahdia, Tunisia., Psychiatry, Mahdia, Tunisia
R. Bouzid
Affiliation:
Department Of Psychiatry, University hospital of Nabeul, Nabeul, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Clozapine is the drug of choice for patients with an unsatisfactory response to classic antipsychotic treatment. Little is known about the involvement of clozapine in the development of parotid disease.

Objectives

Identify the clinical characteristics of Clozapine-induced parotitis through a case and literature review.

Methods

We report the case of a patient with a refractory schizoaffective disorder, bipolar type and who developed recurrent parotitis while taking clozapine. We conducted a literature review based on a PubMed search of articles published on this subject with the following keywords: ‘parotitis clozapine’.

Results

Miss W., 34 years old, suffers from a severe schizoaffective disorder that has been diagnosed for several years. She has received various psychotropic medications. She suffered from frequent relapses that required recurrent hospital admissions. One year ago, a diagnosis of treatment-resistant schizoaffective disorder was made. The decision to introduce clozapine, associated with mood stabilizer treatment, was made on the basis of her treatment refractory symptoms. She experienced considerable sialorrhea after beginning clozapine treatment. Miss W. developed bilateral recurrent swelling over both temporal-mandibular areas after 6 months of treatment. It often appears after eating and lasts from 4 to 6 hours. There was no change in white blood cell count and she was afebrile. An otolaryngologist was consulted and a diagnosis of clozapine-induced parotitis was suggested. A spasmolytic and an anticholinergic treatment were prescribed and clozapine was continued.

Conclusions

This iatrogenic effect of clozapine must be recognized by clinicians in order to be better prevented.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.